Introduction {#tca13046-sec-0005}
============

Non‐small cell lung cancer (NSCLC) is one of the leading causes of cancer‐related death worldwide.[1](#tca13046-bib-0001){ref-type="ref"} Despite recent therapeutic advances, platinum‐based chemotherapy is still a widely used adjuvant therapeutic strategy for patients with advanced NSCLC.[2](#tca13046-bib-0002){ref-type="ref"} Cisplatin is one of the most commonly used chemotherapy drugs, but its use is limited because of acquired drug resistance. Multiple cellular self‐defense adaptations, such as reduced uptake and increased drug efflux, protein inactivation, and increased damage repair, are responsible for cisplatin resistance.[3](#tca13046-bib-0003){ref-type="ref"}, [4](#tca13046-bib-0004){ref-type="ref"} However, how to overcome cisplatin resistance remains a conundrum.

DNA is considered a major target for cisplatin. Cisplatin interacts with DNA mainly in the form of Pt‐d(GpG) di‐adducts, which inhibit cell proliferation and activate the DNA damage response (DDR).[5](#tca13046-bib-0005){ref-type="ref"}, [6](#tca13046-bib-0006){ref-type="ref"} The DNA damage checkpoint is a complex signal transduction pathway that includes ATM, ATR, Chk1, Chk2, the MRN complex, and other checkpoint proteins.[7](#tca13046-bib-0007){ref-type="ref"}, [8](#tca13046-bib-0008){ref-type="ref"} Once the DDR is activated, cell cycle arrest is initiated to repair DNA or induce apoptosis. Disruption of DDR has been identified in various cancers, and strategies targeting DDR have been exploited for the treatment of cancer with radiotherapies or chemotherapies.[9](#tca13046-bib-0009){ref-type="ref"}

*KLF5* is a critical member of the KLF family, which contains a triple zinc finger DNA‐binding domain. *KLF5* regulates numerous key cellular processes, including proliferation, angiogenesis, pluripotency, inflammation, and migration.[10](#tca13046-bib-0010){ref-type="ref"} In cancer, *KLF5* is typically pro‐proliferative by regulating cell cycle progression.[11](#tca13046-bib-0011){ref-type="ref"}, [12](#tca13046-bib-0012){ref-type="ref"} Recently, studies have demonstrated that knockdown of *KLF5* suppresses hypoxia‐induced cisplatin resistance in NSCLC cells.[13](#tca13046-bib-0013){ref-type="ref"} In the intestine, *KLF5* may affect DNA damage repair pathways.[14](#tca13046-bib-0014){ref-type="ref"} Given this background, we hypothesized that *KLF5* may regulate cisplatin resistance through the DDR in NSCLC.

In this study, we compared *KLF5* expression in NSCLC and adjacent normal lung tissues. *KLF5* was knocked down to assess its influence on cell growth with or without cisplatin treatment. Furthermore, we sought to investigate the potential role of *KLF5* in DDR. To our knowledge, this is the first report to confirm that *KLF5* exerts a regulatory effect on key enzymes in the DDR.

Methods {#tca13046-sec-0006}
=======

Cell lines and cell culture {#tca13046-sec-0007}
---------------------------

NSCLC cell lines H1299 and A549 were cultivated in RPMI 1640 (Corning, Logan, UT, USA) supplemented with 10% fetal bovine serum (Corning, Mediatech Inc., Manassas, VA, USA). The cell lines were cultured at 37°C with 5% CO~2~. All of the cell lines used in the study were authenticated by short tandem repeat detection and tested for the presence of mycoplasma.

Patient samples {#tca13046-sec-0008}
---------------

The follow‐up data of 90 patients diagnosed with lung adenocarcinoma between January 2010 and December 2016 were collected from the same hospital. Information including age, gender, and tumor node metastasis (TNM) stage was collected from medical records. Informed consent was obtained from all patients, and the Research Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences approved the research application.

Antibodies and materials {#tca13046-sec-0009}
------------------------

Antibodies (poly \[ADP‐ribose\] polymerase \[PARP\], cleaved PARP, cleaved caspase 3, pH2AX, Chk1, p‐Chk1, Chk2, p‐Chk2, ATM, p‐ATM, ATR, p‐ATR, MRE11, NBS1, RAD50, and glyceraldehyde 3‐phosphate dehydrogenase \[GAPDH\]) used for Western blot analysis were purchased from Cell Signaling Technology (Danvers, MA, USA). KLF5 antibody was purchased from Abcam (ab137676; Cambridge, MA, USA). Cisplatin was purchased from Sigma‐Aldrich (St. Louis, MO, USA) and dissolved in 0.9% NaCl solution.

Immunohistochemical staining {#tca13046-sec-0010}
----------------------------

NSCLC and adjacent normal lung tissues were surgically resected and collected from the Department of Thoracic Surgery (Cancer Hospital, Chinese Academy of Medical Sciences). Briefly, formalin‐fixed and paraffin‐embedded tissue sections were incubated with an antibody against *KLF5* overnight at 4°C and then incubated with an appropriate secondary antibody. We quantitatively scored the tissues according to the percentage of positive staining cells and the staining intensity.[15](#tca13046-bib-0015){ref-type="ref"} A pathologist and two experienced researchers independently scored the slides.

Immunofluorescence {#tca13046-sec-0011}
------------------

Cells (1 × 10^5^) were seeded in chamber slides and cultured overnight. After cisplatin or vehicle treatment, cells were fixed and stained with phosphorylated histone 2AX (pH2AX) antibody overnight at 4°C. The next day, the cells were washed with phosphate buffered saline and then incubated with an appropriate secondary antibody. DAPI (4′,6‐diamidino‐2‐phenylindole, Sigma) was used to counterstain the nuclei. The images were captured via immunofluorescence microscopy using the same exposure time.

Lentivirus vector and reagents {#tca13046-sec-0012}
------------------------------

Two short‐hairpin RNAs (shRNAs), 5′‐cctataattccagagcataaa‐3′ and 5′‐ccctgagttcaccagtatatt‐3′, were synthesized for *KLF5* suppression. They were respectively inserted into the pLKO.1‐puro lentiviral shRNA vector (Generay Biotech Co., Shanghai, China) to produce lentivirus in 293T cells. A549 and H1299 cells were infected with concentrated virus and cultured with complete culture media after 24 hours, followed by selection with puromycin for seven days.

Western blot analysis {#tca13046-sec-0013}
---------------------

A549 and H1299 cells were collected following cisplatin or vehicle treatment. Cells lysates were separated by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis and electrotransferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were incubated with primary antibodies overnight at 4°C and were then incubated with appropriate secondary antibodies.

Cell viability assay {#tca13046-sec-0014}
--------------------

Cell viability was assessed by cell counting kit‐8 (CCK‐8) assay (Dojindo, Kumamoto, Japan) according to the manufacturer\'s instructions. Briefly, A549 or H1299 cells were seeded in 96‐well plates and treated with different doses of cisplatin or the vehicle. Cells were allowed to grow for two days. The optical density was measured at 450 nm.

For colony formation assays, cells were seeded in six‐well plates (600 cells/well) and were allowed to grow for seven days. Cells were then treated with cisplatin (20μM) or the vehicle for 36 hours. Thereafter, colonies were fixed and stained for visualization and counting.

Cell apoptosis analysis {#tca13046-sec-0015}
-----------------------

Cell apoptosis was assessed using an Annexin V‐FITC Apoptosis Detection Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer\'s instructions. Briefly, A539 and H1299 cells were treated with or without cisplatin (20μM) for 48 hours. Cells were then collected, washed with binding buffer, and stained with Annexin V‐FITC and propidium iodide, followed by quantification via flow cytometry.

Statistical analysis {#tca13046-sec-0016}
--------------------

All data were analyzed using GraphPad Prism 6.0 software. Data from specific experiments were compared by Student\'s *t* or *X* ^2^ tests, or Cox regression analysis. Survival curves were plotted using the Kaplan--Meier method and log‐rank test. Data were presented as mean ± standard deviation and \**P* \< 0.05 was considered statistically significant.

Results {#tca13046-sec-0017}
=======

*KLF5* is overexpressed in non‐small cell lung cancer (NSCLC) and is correlated with poor prognosis {#tca13046-sec-0018}
---------------------------------------------------------------------------------------------------

We used immunohistochemical (IHC) staining to detect *KLF5* expression in 90 pairs of lung cancer and adjacent normal tissues. *KLF5* expression was significantly higher in cancer tissues than in adjacent normal tissues (Fig [1](#tca13046-fig-0001){ref-type="fig"}a, Fig [S1](#tca13046-supitem-0001){ref-type="supplementary-material"}). IHC staining also suggested that *KLF5* was mainly localized in the nucleus in NSCLC tissues (Fig [1](#tca13046-fig-0001){ref-type="fig"}b). We then conducted Western blot analysis of five pairs of randomly selected samples to detect KLF5 protein expression, and the results revealed that most tumor tissues showed higher KLF5 expression than paired normal tissues (Fig [1](#tca13046-fig-0001){ref-type="fig"}c).

![*KLF5* is overexpressed in non‐small cell lung cancer (NSCLC) and is correlated with poor prognosis. (**a**) Relative expression levels of *KLF5* in NSCLC and adjacent normal tissues (*n* = 90) were analyzed via immunohistochemical staining (\*\*\**P* \< 0.001). (**b**) Representative images of immunohistological staining of *KLF5* in NSCLC tissues. Scale bar = 20 μm. (**c**) Western blot analysis of *KLF5* expression in NSCLC and adjacent normal tissues. (**d**) Kaplan--Meier analysis suggested that high *KLF5* levels predict a poor overall survival rate (Log‐rank, \**P* = 0.019). ![](TCA-10-1069-g006.jpg "image")Low KLF5 (n = 55), ![](TCA-10-1069-g007.jpg "image") high KLF5 (n = 35). GAPDH, glyceraldehyde 3‐phosphate dehydrogenase.](TCA-10-1069-g001){#tca13046-fig-0001}

Furthermore, we examined the relationship between *KLF5* expression levels and patient survival. *KLF5* expression levels were significantly correlated with patient survival (Fig [1](#tca13046-fig-0001){ref-type="fig"}d), and high *KLF5* expression levels showed excess hazard ratios for death compared to low expression levels (Table [1](#tca13046-tbl-0001){ref-type="table"}). A multivariate Cox regression model revealed a statistically significant reduction in survival with increased *KLF5* expression levels, independent of other important variables in NSCLC (Table [1](#tca13046-tbl-0001){ref-type="table"}).

###### 

Univariate and multivariate analysis of KLF5 expression and other important variables in NSCLC

                *n*     Univariate analysis     Multivariate analysis                           
  ------------- ----- ------------------------ ----------------------- ------------------------ ------------
  Age (years)                                                                                   
  \< 60         45           (Referent)              (Referent)               (Referent)         (Referent)
  ≥ 60          45     1.787 (1.066 to 2.999)           0.026           1.556 (0.921 to 2.626)     0.098
  Gender                                                                                        
  Male          58           (Referent)              (Referent)               (Referent)         (Referent)
  Female        32     0.829 (0.483 to 1.421)           0.495           0.700 (0.401 to 1.220)     0.208
  TNM stage                                                                                     
  I and II      47           (Referent)              (Referent)               (Referent)         (Referent)
  III and IV    43     1.866 (1.112 to 3.132)           0.018           1.841 (1.096 to 3.091)     0.021
  KLF5                                                                                          
  Low           55           (Referent)              (Referent)               (Referent)         (Referent)
  High          35     1.837 (1.097 to 3.078)           0.019           1.810 (1.080 to 3.034)     0.024

*P* values were determined from the Cox proportional hazards model using two‐sided Wald tests. Multivariable model: age, gender, tumor node metastasis (TNM) stage, and *KLF5* expression level. CI, confidence interval; HR, hazard ratio; NSCLC, non‐small cell lung cancer.

*KLF5* knockdown increases cisplatin‐induced cell apoptosis in NSCLC cell lines {#tca13046-sec-0019}
-------------------------------------------------------------------------------

To determine the effect of *KLF5* on the proliferation of NSCLC cells, we knocked down *KLF5* in A549 and H1299 cell lines via lentiviral infection (Fig [2](#tca13046-fig-0002){ref-type="fig"}a). Cell viability was evaluated by CCK‐8 assay. Our results showed that the proliferation rate of cells subjected to *KLF5* knockdown was not significantly different from the control under vehicle treatment (Fig [2](#tca13046-fig-0002){ref-type="fig"}b). However, under different doses of cisplatin treatment, *KLF5* knockdown significantly suppressed the proliferative ability of A549 and H1299 cells compared to the control (Fig [2](#tca13046-fig-0002){ref-type="fig"}c). We then reevaluated cell proliferation using colony formation assay and found that the number and size of colonies in the *KLF5*‐knockdown groups were markedly lower and smaller than in the control group under cisplatin treatment, respectively (Fig [2](#tca13046-fig-0002){ref-type="fig"}d). These results show that *KLF5* knockdown led to reduced cell proliferative ability in response to cisplatin.

![*KLF5* knockdown reduces cell survival rates in response to cisplatin in non‐small cell lung cancer (NSCLC) cell lines. (**a**) Knockdown of *KLF5* with two short‐hairpin RNAs in A549 and H1299 cell lines. (**b**) Relative viability of cells subjected to *KLF5* knockdown, measured via cell counting kit‐8 (CCK‐8) assay. (**c**) Relative viability of cells treated with different doses of cisplatin for 48 hours, measured via the CCK‐8 assay in indicated cell lines. (**d**) The effect of *KLF5* on proliferation under cisplatin or vehicle treatment was measured by colony formation assay. ![](TCA-10-1069-g008.jpg "image") shvec, ![](TCA-10-1069-g009.jpg "image") shKLF5\#1, ![](TCA-10-1069-g010.jpg "image") shKLF5\#2. Data are shown as mean ± standard deviation. *P* values were determined by two‐tailed Student\'s *t* test (ns, not significant; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001). GAPDH, glyceraldehyde 3‐phosphate dehydrogenase.](TCA-10-1069-g002){#tca13046-fig-0002}

The effect of *KLF5* on NSCLC cell apoptosis was evaluated by flow cytometry analysis. *KLF5* knockdown had no significant effect on the cell apoptotic rate (Fig [3](#tca13046-fig-0003){ref-type="fig"}a) except after 48 hours of treatment with cisplatin, at which time the rate significantly increased (Fig [3](#tca13046-fig-0003){ref-type="fig"}b). To further investigate the effect of *KLF5* knockdown on cell apoptosis, apoptosis‐related proteins were detected by Western blot analysis. We found that *KLF5* knockdown significantly increased the levels of the intrinsic apoptosis‐inducing proteins, cleaved PARP and cleaved caspase 3, after treatment with cisplatin (Fig [3](#tca13046-fig-0003){ref-type="fig"}c). These results demonstrate that *KLF5* knockdown increases cell apoptosis induced by cisplatin.

![*KLF5* knockdown promotes cisplatin‐induced cell apoptosis in non‐small cell lung cancer (NSCLC) cell lines. (**a**,**b**) Cells subjected to *KLF5* knockdown were treated with cisplatin (20μM) or the vehicle for 48 hours and analyzed via flow cytometry. Apoptosis was measured with FACS‐based annexin‐V/propidium iodide (PI) double staining. The proportion of apoptotic cells within the total number of cells was used to evaluate cell apoptosis. (**c**) The expression of apoptosis‐inducing proteins was analyzed by Western blotting following cisplatin (20μM) treatment. Data are shown as mean ± SD. *P* values were determined by two‐tailed Student\'s t test (ns, not significant; \*\*\**P* \< 0.001). GAPDH, glyceraldehyde 3‐phosphate dehydrogenase; PARP, poly (ADP‐ribose) polymerase; PI, propidium iodide.](TCA-10-1069-g003){#tca13046-fig-0003}

*KLF5* knockdown decreases DNA repair potential in NSCLC cell lines {#tca13046-sec-0020}
-------------------------------------------------------------------

The activation of checkpoint pathways in response to DNA damage leads to cell cycle arrest to repair damaged DNA. pH2AX, a widely used indicator of the presence of damaged DNA, is required for checkpoint‐mediated cell cycle arrest and DNA repair following double‐stranded DNA breaks.[16](#tca13046-bib-0016){ref-type="ref"} We assessed the expression of nuclear pH2AX (S139) through immunofluorescence analysis. Under cisplatin treatment, the pH2AX staining intensity in A549 and H1299 cells increased significantly compared to the control (Fig [4](#tca13046-fig-0004){ref-type="fig"}a). However, when cells were targeted with *KLF5* shRNA, the pH2AX nuclear expression induced by cisplatin was attenuated (Fig [4](#tca13046-fig-0004){ref-type="fig"}a,b). We confirmed this result through Western blot analysis (Fig [5](#tca13046-fig-0005){ref-type="fig"}a). These results reveal that *KLF5* knockdown decreases DNA repair potential by downregulating pH2AX S139 phosphorylation levels.

![*KLF5* knockdown decreases the DNA repair potential by regulating H2AX S139 phosphorylation. (**a**) Immunofluorescence analysis showed increased phosphorylation of H2AX after cisplatin (10μM) treatment for 24 hours. As shown in the figure, *KLF5* knockdown abrogates cisplatin‐induced H2AX S139 phosphorylation. All images were captured using the same exposure time. Scale bar = 20μm. (**b**) Cells with pH2AX nuclear foci staining were quantified and statistically analyzed. Data are shown as mean ± standard deviation. *P* values were determined by two‐tailed Student\'s *t* test (ns, not significant; \**P* \< 0.05; \*\**P* \< 0.01). DAPI, 4′,6‐diamidino‐2‐phenylindole.](TCA-10-1069-g004){#tca13046-fig-0004}

![*KLF5* knockdown regulates checkpoint proteins in the DNA damage response (DDR). (**a**) Western blotting showed that *KLF5* knockdown attenuated the activating phosphorylation of H2AX (S139), Chk1 (S345), and Chk2 (T68) after cisplatin (10 μM) treatment for 24 hours. (**b**) Knockdown of *KLF5* affects phosphorylation of Chk1 and Chk2, but not ATM or ATR. GAPDH, glyceraldehyde 3‐phosphate dehydrogenase.](TCA-10-1069-g005){#tca13046-fig-0005}

*KLF5* knockdown regulates DNA damage checkpoint kinases in NSCLC cell lines {#tca13046-sec-0021}
----------------------------------------------------------------------------

To investigate the role of *KLF5* in checkpoint activation, we examined the effect of *KLF5* knockdown on the activating phosphorylation of several key checkpoint proteins, including ATM, ATR, and downstream checkpoint proteins (Chk1, Chk2, and MRN complex) in A549 and H1299 cells. *KLF5* silencing attenuated the activating phosphorylation of Chk1 (S345) and Chk2 (T68) but not ATM (S1981) in response to DNA damage induced by cisplatin (Fig [5](#tca13046-fig-0005){ref-type="fig"}a). *KLF5* knockdown did not alter the total protein levels of these checkpoint proteins in A549 and H1299 cell lines (Fig [5](#tca13046-fig-0005){ref-type="fig"}b,Fig [S2](#tca13046-supitem-0002){ref-type="supplementary-material"}); however, the total Chk2 protein levels significantly decreased under cisplatin treatment (Fig [5](#tca13046-fig-0005){ref-type="fig"}a). Consistent with the results of a previous study, DNA damage‐induced autophosphorylation on S379 led to the ubiquitination of Chk2 by a Cullin1‐containing E3 ligase, which could cause degradation of Chk2.[17](#tca13046-bib-0017){ref-type="ref"} These results demonstrate that *KLF5* knockdown indeed attenuates DNA damage checkpoint activation in NSCLC cells in response to cisplatin.

Discussion {#tca13046-sec-0022}
==========

Lung cancer development and progression are multistep processes characterized by aberrant genetic changes and protein expression. Recent studies have revealed that *KLF5* is one of a group of new significantly mutated genes in NSCLC.[18](#tca13046-bib-0018){ref-type="ref"} Cancer type‐specific hotspot mutations within a zinc‐finger DNA binding domain of *KLF5* change its DNA binding specificity and affect cellular transcription.[19](#tca13046-bib-0019){ref-type="ref"} Multiple studies have shown that *KLF5* plays a role in cisplatin resistance in various tumors. In colorectal cancer, *KLF5* is predictive for cell line and patient response to platinum agents.[20](#tca13046-bib-0020){ref-type="ref"} In ovarian cancer cell lines, silencing *KLF5* by small interfering RNA sensitizes cells to apoptosis induced by cisplatin.[21](#tca13046-bib-0021){ref-type="ref"} A previous study reported that *KLF5* knockdown could suppress hypoxia‐induced cisplatin resistance in NSCLC, probably via inactivation of the PI3K/Akt/mTOR pathway;[13](#tca13046-bib-0013){ref-type="ref"} however, the study failed to mention the prognostic value of *KLF5* and its underlying roles in the DDR in NSCLC.

In this study, we showed that *KLF5* is upregulated in NSCLC via IHC staining in 90 pairs of NSCLC and adjacent normal tissues. *KLF5* expression levels were significantly correlated with survival duration. These results indicate that *KLF5* overexpression is a common feature in NSCLC and may serve as a valuable prognostic biomarker. To further investigate the function of *KLF5*, we stably knocked down *KLF5* in NSCLC cell lines. Our results showed that *KLF5* knockdown significantly reduced the survival rate in response to cisplatin by upregulating apoptosis‐inducing proteins, cleaved PARP and cleaved caspase 3, in A549 and H1299 cell lines. Thus, *KLF5* may serve as a biomarker to predict cisplatin treatment response.

Many anticancer agents cause DNA damage, resulting in the activation of DNA damage checkpoints and proliferation arrest. As a member of the histone H2A family, H2AX is required for DNA damage signal amplification and the subsequent recruitment of repair factors to nuclear foci after DNA damage.[22](#tca13046-bib-0022){ref-type="ref"} The suppression of pH2AX decreases DNA repair potential. In our study, *KLF5* knockdown attenuated cisplatin‐induced H2AX S139 phosphorylation in NSCLC cells, suggesting that *KLF5* knockdown can decrease the DNA repair potential in NSCLC cells.

In response to DNA injury, critical kinases Chk1 and Chk2 were activated. ATR phosphorylates Chk1 at S317 and S345, resulting in a marked increase in Chk1 activity.[23](#tca13046-bib-0023){ref-type="ref"} ATM phosphorylates Chk2 at T68, which is thought to activate Chk2.[24](#tca13046-bib-0024){ref-type="ref"} Both Chk1 and Chk2 activation converge to inactivate members of the Cdc25 family and then arrest cells in the G2/M phase.[25](#tca13046-bib-0025){ref-type="ref"} In this study, phosphorylation of Chk1 (S345) and Chk2 (T68) was significantly increased under cisplatin treatment. *KLF5* knockdown attenuated the phosphorylation of Chk1 and Chk2 induced by cisplatin and reversed their inhibitory effect on the cell cycle. In combination with pH2AX (S139) suppression, *KLF5* knockdown permits cells with broken or damaged DNA strands to enter mitosis, resulting in mitotic catastrophe, leading to cell death.[26](#tca13046-bib-0026){ref-type="ref"} We investigated two major kinases, ATM and ATR, which phosphorylate Chk2 and Chk1, and found that the phosphorylation level of ATM (S1891) or ATR (S428) was not affected by *KLF5* suppression. We propose that other regulatory mechanisms might be involved. Manila *et al*. demonstrated that IGF‐1 decreases radiation‐induced phosphorylation of Chk1 at S345 or S296 via the PI3K/AKT pathway.[27](#tca13046-bib-0027){ref-type="ref"} Notably, various studies have confirmed that *KLF5* plays critical roles in the PI3K/Akt/mTOR pathway.[11](#tca13046-bib-0011){ref-type="ref"}, [13](#tca13046-bib-0013){ref-type="ref"} Moreover, phosphorylation of Chk2 at T68 in response to DNA damage occurs in ATM‐deficient cells, suggesting that kinases other than ATM may be involved.[28](#tca13046-bib-0028){ref-type="ref"} Thus, this study provides proof for further investigation of the role of *KLF5* in regulating the phosphorylation of Chk1 and Chk2.

In conclusion, our results show that *KLF5* knockdown can inhibit DNA repair in NSCLC cell lines by suppressing phosphorylation of H2AX, Chk1, and Chk2. Moreover, *KLF5* is commonly overexpressed in NSCLC tissues, and high KLF5 predicts poor overall survival. Our study indicated that *KLF5* may be a potential therapeutic target in patients with cisplatin resistance.
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###### 

**Supplementary Fig. 1** Hematoxylin and eosin (H&E) and immunohistological staining of *KLF5* in non‐small cell lung cancer (NSCLC) and adjacent normal tissues from four different cases. Scale bar = 20μm.

###### 

Click here for additional data file.

###### 

**Supplementary Fig. 2** Western blot analysis of the MRN complex in A549 and H1299 cell lines subjected to *KLF5* knockdown.

###### 

Click here for additional data file.
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